🧬 New Technology added at Pharmidex in house now: Enhancing Precision in Coagulation Testing🧬
June 9, 2025

We're excited to announce the integration of the Sysmex CA-660 semi-automated Coagulation Analyzer into our lab infrastructure.


This compact yet powerful instrument brings clinical-grade coagulation testing to our preclinical workflows, enabling:


✅ High-precision clotting, chromogenic & immunoassays

✅ Low sample & reagent volume needs ideal for preclinical models

✅ Robust data reproducibility for decision-critical insights

✅ Easy-to-use interface for rapid turnaround


With the CA-660, Pharmidex is further enhancing its capacity to deliver accurate, consistent and fast coagulation studies, a key component in safety pharmacology, clinical pathology and drug development.


This system supports our mission to provide high-quality bioanalytical, DMPK and toxicology services to our partners in biotech and pharma.

Sysmex CA-660 semi-automated Coagulation Analyzer

#Pharmidex #Sysmex #CoagulationTesting #DrugDevelopment #PreclinicalResearch #Bioanalysis #DMPK #LifeSciences #InnovationInBiotech

Pharmidex Histology Services: Precision You Can Trust
September 8, 2025
At Pharmidex , we deliver comprehensive histology solutions designed to support preclinical and clinical research with accuracy and reliability. 🔬 From sample to slide, our services include: tissue processing, embedding, microtomy, routine and special staining, digital imaging and slide scanning all underpinned by rigorous quality control and expert scientific oversight. With specialist capabilities and high-throughput workflows, we help researchers generate high-quality, reproducible data across toxicology, oncology, CNS and beyond. 👉 Learn more: pharmidex.com/histology
? Expanding our integrated capabilities in autoimmune research
September 3, 2025
At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: ✔️ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression ✔️ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs ✔️ Pharmacological intervention studies, including established treatments such as Fingolimod for validation This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. 👉 Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.
Pharmidex attending DMDG 51st Open Meeting 2025.
September 1, 2025
We’re delighted to share that Martin Barrett , our Head of Business Development, and Rob Jenkins , our Bioanalytical Scientist, will be attending the 51st Open Meeting 2025. This event is a fantastic opportunity to connect with industry leaders, share insights and build new collaborations. Martin and Rob are looking forward to meeting fellow attendees, exchanging ideas and exploring ways to create impactful partnerships that advance drug discovery and development. 🤝 If you’re attending, don’t hesitate to reach out they’ll be happy to connect, discuss your projects, and explore potential synergies.
More Posts